國藥科技股份(08156.HK)擬發行合共1.92億股貸款資本化股份
格隆匯6月9日丨國藥科技股份(08156.HK)公佈,於2021年6月8日,公司與五名認購人各自訂立貸款資本化協議,五名認購人有條件同意認購,而公司有條件同意配發及發行合共1.92億股貸款資本化股份,相當於現有已發行股份數量約4.43%;經配發所有貸款資本化股份擴大後的已發行股份數目約4.24%,每股按貸款資本化認購價每股0.26港元。認購人根據貸款資本化協議應付的認購金額須透過將公司欠各認購人的貸款項下的未償還本金額資本化而支付。
五名認購人為公司主席、執行董事、行政總裁及前端投資股份有限公司的董事陳霆先生;公司非執行董事及前端投資股份有限公司的董事兼股東張桂蘭女士;公司附屬公司董事的配偶伍碧燕女士;陳文亮先生;張曉峯先生。
董事認為,貸款資本化協議項下的貸款資本化將使公司能夠在不動用集團現有財務資源的情況下結清公司欠認購人的未償還款項,同時降低負債水平,從而加強集團的財務狀況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.